Good MorningEquity markets rebounded on Wednesday following better-than-expected results from Target. The big box retailer reported strength on the top and bottom lines and maintained its guidance for the year. The caveat is that guidance for the 2nd quarter was reduced due to weakening consumer trends, and the weakness may not be contained to the quarter. If the weakness lingers, and there is no reason to think it won't, Target will reduce its guidance later in the year.
The S&P 500 gained more than 1.0% at the day's high to confirm support at the 30-day moving average. However, the move was capped by resistance at the 4,150 level and may not get any higher. The 4,150 level has been an impossible line for the market to cross for over a year, and nothing in the outlook says that will change now. Even if the index can grind higher, the 4,300 is another line in the sand that will cap gains unless the outlook for the 2nd half begins to improve. Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Technology | |
Shares of video game developer Unity Software Inc. (NYSE: U) are trading for the same price this time last year. After reaching all-time highs in November of 2021, the San Francisco headquartered stock was abruptly decimated, like many of its tech brethren. This time last year, investors were reel... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Retail/Wholesale | |
Target (NYSE: TGT) reported a better-than-expected quarter driven by the underlying momentum within the US economy. That’s the good news. The bad news is that outlook is weak, echoing home improvement retailer Home Depot (NYSE: HD), and gives further evidence of a looming recession in the US... Read the Full Story |
|
Industrials | |
Shares of Siemens Aktiengesellschaft (OTCMKTS: SIEGY) showcased a massive 78% rally after 2022, full of natural growth, paired with enriched multiples on these expanding financials. Today, Siemens chart shows that the stock is consolidating around the $77-$80 range as investors look for more direc... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Consumer Staples | |
Whether measured in Celsius or Fahrenheit, Celsius Holdings, Inc. (NASDAQ: CELH) is red hot!
Shares of the healthy energy drink maker soared to an all-time high last week following another outstanding earnings report. After rising 48% in 2021 and 40% last year, the stock is up more than 20% year-... Read the Full Story |
|
Technology | |
Whether you believe markets are always efficient, or whether you believe some stocks are mispriced, you undoubtedly want to buy low and sell high.
Some stocks are considered mispriced if they are undervalued, relative to their intrinsic value. Typically, value sectors include utilities, industr... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Transportation | |
Danaos Corporation (NYSE: DAC) is not an exciting investment unless you like cash-generating machines that pay high-yielding dividends. The company is one of the world’s largest independent container ship operators, and the business is good despite macro-uncertainty gripping the economy. The... Read the Full Story |
|
Consumer Staples | |
Beyond Meat (NASDAQ: BYND) is turning a corner. After a year of recovering from dashed hopes related to its partnerships with McDonald’s (NYSE: MCD), Yum! Brands (NYSE: YUM), and PepsiCo (NASDAQ: PEP), the company is on track for cash-flow-positive operations by the end of the year. The comp... Read the Full Story |
|
Finance | |
At the most recent Berkshire Hathaway Inc. (NYSE:BRK.B) investors conference in early May, Warren Buffett offered some insights into his most recent buys and sells, but more detail was released in a regulatory filing on May 15, after the market’s close.
At the conference, Buffett mentioned... Read the Full Story |
|
Retail/Wholesale | |
Shares of Shake Shack Inc. (NYSE: SHAK) shimmied higher on news Engaged Capital, an activist investor was seeking a bigger role in the company’s operations, including board seats.
The stock gapped up 7.81% on May 15, as investors were optimistic that Engaged could bring some shakeups to boo... Read the Full Story |
|
Retail/Wholesale | |
Shares of Walt Disney (NYSE: DIS) are trading at one of their lowest valuations since 2026 (excluding COVID-19 adverse effects) after a two-year downtrend that started on March 2021; CEO Bob Iger is looking to turn things around and revive the stock price into new highs. The Disney chart is consol... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. | | View Today's Stock Pick |
|
